EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer

被引：0
|
作者：
Jonathan E Dowell
John D Minna
机构：
[1] Internal Medicine at the University of Texas Southwestern Medical Center and serves as the Chief of Hematology/Oncology at the Dallas VA Medical Center,
[2] Internal Medicine and Pharmacology,undefined
[3] Director of the Hamon Center for Therapeutic Oncology Research and the Moncrief Center for Cancer Genetics,undefined
[4] and a NCI Special Program of Research Excellence at the University of Texas Southwestern Medical Center,undefined
来源：
Nature Clinical Practice Oncology | 2006年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Although the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib can produce dramatic and durable tumor responses, not all patients with non-small-cell lung cancer (NSCLC) benefit from these drugs. This Viewpoint discusses the molecular correlates of response for these agents in patients with NSCLC.
引用
收藏
页码：170 / 171
页数：1
相关论文
共 50 条
  • [1] EGFR mutations and molecularly targeted therapy:: a new era in the treatment of lung cancer
    Dowell, JE
    Minna, JD
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (04): : 170 - 171
  • [2] Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors
    Haber, D. A.
    Bell, D. W.
    Sordella, R.
    Kwak, E. L.
    Godin-Heymann, N.
    Sharma, S. V.
    Lynch, T. J.
    Settleman, J.
    Molecular Approaches to Controlling Cancer, 2005, 70 : 419 - 426
  • [3] EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy
    Noronha, Vanita
    Prabhash, Kumar
    Thavamani, Abhishek
    Chougule, Anuradha
    Purandare, Nilendu
    Joshi, Amit
    Sharma, Rashmi
    Desai, Saral
    Jambekar, Nirmala
    Dutt, Amit
    Mulherkar, Rita
    PLOS ONE, 2013, 8 (04):
  • [4] Targeted therapy in small cell lung cancer: A new era?
    Capelletto, Enrica
    Mariniello, Annapaola
    Novello, Silvia
    LUNG CANCER, 2017, 108 : 252 - 253
  • [5] New molecularly targeted therapies for lung cancer
    Sun, Sophie
    Schiller, Joan H.
    Spinola, Monica
    Minna, John D.
    JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (10): : 2740 - 2750
  • [6] Combination therapy with molecularly targeted agents in lung cancer
    Okamoto, Isamu
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies
    Malouf, G.
    Baudin, E.
    Soria, J. -C.
    Schlumberger, M.
    BULLETIN DU CANCER, 2009, 96 (01) : 95 - 101
  • [8] EGFR mutations and lung cancer: the era of precision medicine in oncology
    Sekerus, V.
    Andrijevic, L.
    Lazin, S.
    Potic, M.
    Vuckovic, D.
    Lovrenski, A.
    Tegeltija, D.
    Andrijevic, I.
    FEBS OPEN BIO, 2022, 12 : 87 - 88
  • [9] Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy
    Jin, Jing
    Wu, Xu
    Yin, Jianhua
    Li, Mingxing
    Shen, Jing
    Li, Jing
    Zhao, Yueshui
    Zhao, Qijie
    Wu, Jingbo
    Wen, Qinglian
    Cho, Chi Hin
    Yi, Tao
    Xiao, Zhangang
    Qu, Liping
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [10] Molecularly targeted gemcitabine-loaded nanoparticulate system towards the treatment of EGFR overexpressing lung cancer
    Wang, Xian-Bao
    Zhou, Hai-Yan
    BIOMEDICINE & PHARMACOTHERAPY, 2015, 70 : 123 - 128
12345